Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

Peer Review reports

Original Submission
2 Apr 2014	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
2 Jun 2014	Reviewed	Reviewer Report - Domenico Capone
2 Jun 2014	Reviewed	Reviewer Report - Giovanni Tarantino
28 Aug 2014	Author responded	Author comments - Jennifer Stephens
Resubmission - Version 3
28 Aug 2014	Submitted	Manuscript version 3
28 Aug 2014	Author responded	Author comments - Jennifer Stephens
Resubmission - Version 4
28 Aug 2014	Submitted	Manuscript version 4
Publishing
16 Sep 2014	Editorially accepted
24 Sep 2014	Article published	10.1186/2050-6511-15-52

Back to article page